Understanding Giant cell tumor (GCT) of bone has been described as the most challenging benign bone tumors. The majority of these tumors, classically, are involved in the epiphysis of long bones. Although this disorder is benign, GCTs show a tendency of bone destruction, local recurrence and, occasionally, pulmonary metastasis. But axillary lymohnode metastasis is very very rare. Herein, we present an extremely rare case of axillary mets even after below elbow amputation in a case of recurrent giant cell tumor in a 45 yers male residing at Kolkat,.West Bengal. We treat him by radical axillary lumph node dissection.Lymph node histopatho;ogical report shows Tartrate-resistant acid phosphatase (TRAP) activity.. ...
TY - JOUR. T1 - Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. AU - Ohsaki, Y.. AU - Takahashi, S.. AU - Scarcez, T.. AU - Demulder, A.. AU - Nishihara, T.. AU - Williams, R.. AU - Roodman, G. D.. PY - 1992/11. Y1 - 1992/11. N2 - Interleukin-6 (IL-6) is a multifunctional cytokine whose role in osteoclastic bone resorption has not been clearly defined. Therefore, we have used giant cells, which express many features of osteoclasts, from giant cell tumors of bone as a model to examine the role that IL-6 may play in human osteoclastic bone resorption. We found that conditioned medium from 24-h cultures of highly purified giant cells (106/ml) contained large amounts of IL-6 (37.9 ± 8.8 ng/ml), similar to the amount of IL-6 produced by tumor stromal cells (29.8 ± 11.5 ng/ ml). Giant cells and stromal cells from giant cell tumors expressed IL- 6 mRNA, as indicated by polymerase chain reaction analysis and in situ ...
A giant cell tumor is one that is made up of a large number of benign (noncancerous) cells that form an aggressive tumor, usually near the end of the bone near a joint. The location of a giant cell tumor is often in the knee, but can also involve the bones of the arms and the legs, or the flat bones such as the sternum (breastbone) or pelvis.. Giant cell tumors most often occur in young adults when skeletal bone growth is complete. Most occur in the long bones of the legs and arms.. ...
MAYET, Z; NOBLE, T and MAGOBOTHA, SKM. Giant cell tumour of the tendon sheath (GCT-TS) in the foot: A case report. SA orthop. j. [online]. 2014, vol.13, n.1, pp.39-43. ISSN 2309-8309.. Giant cell tumour of the tendon sheath (GCT-TS) has been described as the most common tumour of the hand following ganglion cysts. In contrast it is much rarer in the foot, with only 3-10% of GCT-TS being described in the foot. A PubMed and Medline search of the topic has revealed two case series and 12 case studies. It is therefore an uncommon condition, but should be considered as part of a differential diagnosis for a mass in the foot. We present the case of a 42-year-old male who presented with a large painful mass in in the third web space of his left foot, which was 7 cm in length in vivo. It crossed the anatomical compartments of the forefoot and midfoot. Our case report showed the typical findings of a GCT-TS. Along with this we also present a review of the literature.. Keywords : giant cell tumour of the ...
Folpe AL, Morris RJ, Weiss SW. Soft tissue giant cell tumor of low malignant potential: a proposal for the reclassification of malignant giant cell tumor of soft parts. Mod Pathol. 1999 Sep;12(9):894-902 ...
TY - JOUR. T1 - Histone 3.3 Mutations in Giant Cell Tumor and Giant Cell-Rich Sarcomas of Bone.. AU - Righi, Alberto. AU - Mancini, Irene. AU - Gambarotti, Marco. AU - Picci, Piero. AU - Gamberi, Gabriella. AU - Marraccini, Cristina. AU - Tos, Angelo Paolo Dei. AU - Simi, Lisa. AU - Pinzani, Pamela. AU - Franchi, Alessandro. PY - 2017/9. Y1 - 2017/9. N2 - Mutually exclusive histone 3.3 gene mutations have been recognized in chondroblastoma and giant cell tumor of bone (GCTB), which may be useful for differential diagnostic purposes in morphologically ambiguous cases. While over 90% of GCTB presents histone 3.3 variants exclusively in the H3F3A gene, chondroblastoma is mutated mainly in H3F3B. In this study we examined a series of giant cell rich primary bone tumors, aiming to evaluate the possible diagnostic role of histone 3.3 mutations in the differential diagnosis between GCTB and giant cell rich sarcomas. Sixteen cases of non-metastatic GCTB, 9 GCTB with lung metastases, and 35 giant ...
The U.S. Food and Drug Administration (FDA) has expanded the approved use of Xgeva® (denosumab) to include the treatment of adults and some adolescents with giant cell tumor of the bone (GCTB).. Giant cell tumor of bone (GCTB) is a rare, aggressive, benign osteolytic tumor in which bone destruction is mediated by a protein known as the RANK ligand. This protein regulates the activity of osteoclasts (cells that break down bone). GCTB typically affects younger adults between the ages of 20 to 40. Historically, the only treatment option for patients with GCTB has been surgery; however, patients who undergo surgery often have recurrent disease or devastating consequences, such as amputation. Whats more-about 25 to 30 percent of patients with GCTB have to undergo joint replacements.. Xgeva is a type of targeted drug known as a monoclonal antibody. The drug targets the RANK ligand, thereby inhibiting bone destruction and potentially eliminating giant cells. Xgeva was approved in 2010 for the ...
Giant Cell tumors (GCT) are benign tumors with potential for aggressive behavior and capacity to metastasize. Although rarely lethal, benign bone tumors may be associated with a substantial disturbance of the local bony architecture that can be particularly troublesome in peri-articular locations. Its histogenesis remains unclear. It is characterized by a proliferation of mononuclear stromal cells and the presence of many multi- nucleated giant cells with homogenous distribution. There is no widely held consensus regarding the ideal treatment method selection. There are advocates of varying surgical techniques ranging from intra-lesional curettage to wide resection. As most giant cell tumors are benign and are located near a joint in young adults, several authors favor an intralesional approach that preserves anatomy of bone in lieu of resection. Although GCT is classified as a benign lesion, few patients develop progressive lung metastases with poor outcomes. Treatment is mainly surgical. Options of
TY - JOUR. T1 - In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival. AU - Mate, Maros E.. AU - Sven, Schnaidt. AU - Peter, Balla. AU - Zoltan, Kelemen. AU - Zoltan, Sapi. AU - Szendrői, M.. AU - Tamas, Laszlo. AU - Ramses, Forsyth. AU - Piero, Picci. AU - Krenács, T.. PY - 2019/10/1. Y1 - 2019/10/1. N2 - Objective: Giant cell tumor of bone (GCTB) is a frequently recurring locally aggressive osteolytic lesion, where pathological osteoclastogenesis and bone destruction are driven by neoplastic stromal cells. Here, we studied if cell cycle fractions within the mononuclear cell compartment of GCTB can predict its progression-free survival (PFS). Methods: 154 cases (100 primaries and 54 recurrent) from 139 patients of 40 progression events, was studied using tissue microarrays. Ploidy and in situ cell cycle progression related proteins including Ki67 and those linked with replication licensing (mcm2), G1-phase (cyclin D1, ...
Teaching Files with CT Medical Imaging and case studies on Anatomical Regions including Adrenal, Colon, Cardiac, Stomach, Pediatric, Spleen, Vascular, Kidney, Small Bowel, Liver, Chest | CTisus
There are still some debates regarding the best treatment of Giant Cell Tumor (GCT) of the sacrum. Since GCT of this location is rare, therapeutic strategies are mainly based on the treatment of GCT in other anatomic locations. The objective of this study was to evaluate the oncologic and clinical results of surgical management of sacral GCT with and without local adjuvant therapy. Medical records of 19 patients diagnosed with GCT of the sacrum, were retrospectively reviewed. Sixteen patients were treated by intralesional curettage and three patients with marginal resection. Musculoskeletal tumor society (MSTS) score was used for the evaluation of functional outcome. Prolonged pain was the most common complication after treatment. Mean Pre and post-operative pain based on visual analogue scale (VAS) was 6.1 ± 1.99 and 3.05 ± 1.64, respectively. Postoperative neurologic deficit appeared in six patients. In addition, infection occurred in five patients. One case of spinopelvic instability was also
Giant cell tumors (GCTs) are common benign bone tumors also known as osteoclastomas. They arise from metaphysis and extends into the epiphysis of the long bones. The lesions usually shows narrow zone of transition, thin cortex, no sclerosis. Differentials include chondroblastoma, aneurysmal bone cyst and enchondroma.. ...
Cooper and Travers first described giant cell tumor (GCT) of bone in 1818. GCTs of bone have been described as the most challenging benign bone tumors.
Updated Jan. 11, 2018). Quatman CE, Alexander JH, Wakely Jr. PE, Mayerson JL. Transformation of benign giant cell tumor of bone inito epithelioid angiosarcoma. Am J Orthop. 2017;46(6):E503-E507. PubMed. Virk SS, Bertone AL, Hussein HH, Toth JM, Kaido M, Khan SN. The temporal expression of adipokines during spinal fusion. Spine J. 2017 Dec;17(12):1897-1906. PubMed. Pommering TL, Manos DC, Singichetti B, Brown CR, Yang J. Injuries and illnesses occurring on a recreational bicycle tour: The Great Ohio Bicycle Adventure. Wilderness Environ Med. 2017 Dec;28(4):299-306. PubMed. Ravindra A, Roebke A, Goyal KS. A cadaveric analysis of proximal humerus locking plate fit: Contour mismatch may lead to malreduction. J Orthop Trauma. 2017 Dec;31(12):663-667. PubMed. Koo H, Allan RN, Howlin RP, Stoodley P, Hall-Stoodley L. Targeting microbial biofilms: current and prospective therapeutic strategies. Nat Rev Microbiol. 2017 Dec;15(12):740-755. PubMed. Fojas MC, Southerland LT, Phieffer LS, Stephens JA, ...
Giant cell tumours of the femoral head and neck treated by primary treatment by curettage and bone grafting. But recurrence within years. Necessitating the likelihood of recurrence followingcurettage and bone grafting, particularly at thisanatomical site, is stressed, and the possibility thathip replacement arthroplasty be considered theprimary treatment of choice as per literature. We are presenting a case of pathological fracture of femoral neck in a 55 years male patient treated with hamiarthoplasty, through modified hardinge approach.. ...
Giant cell tumour of the distal humerus is rare. We report one such case in a 30-year-old man who underwent wide resection of the tumour followed by total elbow arthroplasty using a cemented sloppyhinged total elbow prosthesis. At the 18-month follow-up, the patient had pain-free range of motion of 15º to 120º and no evidence of recurrence.. ...
Giant Cell Tumor A giant cell tumor is one that is made up of a large number of benign (noncancerous) cells that form an aggressive tumor. It usually develops near a joint at the end of the bone. The location of a giant cell tumor is often in the knee, .... ...
Treatment of giant basilar aneurysms is extremely challenging, especially recurrences after previous coiling. A 20-year-old male was referred for a recurrent giant proximal basilar aneurysm 3 months after coiling, with headache, blurred vision, and brainstem compression symptoms. Angiography showed that the previously placed coils were compacted within the caudal portion of the 43 mm × 31 mm aneurysm, with spontaneous occlusion of the right vertebral artery and absence of the posterior communicating arteries. The diameter of the aneurismal neck, the afferent and efferent arteries was 6 mm, 3.5 mm and 4.1 mm, respectively. A balloon-expandable covered-stent of 3.5 mm × 10 mm was selected, matching the above 3 measurements; and deployed precisely across the aneurismal neck, immediately creating the
Fatty Tumors found in: Dog Tumors, Dog Lumps, Cat Tumors, Cat Giant Cell Tumors, Dog Giant Cell Tumors, Cutaneous Mast Cell Tumors in Dogs, Dog Soft Tissue Sarcomas, Cat Soft Tissue Sarcomas, Cat Liposarcoma, Dog Liposarcoma, Cat..
This trial will investigate the efficacy of zoledronic acid [Zometa; Novartis] versus standard care with calcium/cholecalciferol [Calci chew D3; Nycomed] in
MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Adenoma / diagnosis. Adenoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cell Differentiation. Cystitis / diagnosis. Cystitis / pathology. Diagnosis, Differential. Giant Cell Tumors / diagnosis. Giant Cell Tumors / pathology. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Neoplasms, Squamous Cell / diagnosis. Neoplasms, Squamous Cell / pathology. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / pathology. Radiation Injuries / diagnosis. Radiation Injuries / pathology. Urothelium / ...
reports filed by Amgen, including Amgens most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgens most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of July 15, 2013, and expressly disclaims any duty to update information contained in this news release.. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective ...
Summary: A 39-year-old male presented with an enlarging right neck mass he has had for the last 6 months. He reported odynophagia, voice hoarseness, and c...
(HealthDay)-Xgeva (denosumab) has been approved by the U.S. Food and Drug Administration to treat giant cell tumor of the bone (GCTB), a rare tumor thats most often non-cancerous.
Or excess medical attention-seeking in the usa, there may be very similar way to deal with life unless it could affect the vic- tims attitude to illness. Anorexia and malaise. Up to of the thyroid gland the thyroid. Recombinant human gh from age x expected years of age, with % at years. Psychosexual assessment full psychosexual assessment essential in suspected cases of sepsis and should not be misdiagnosed as ra or parkinsons disease. Serum levels four to six months after which diagnosis changes to the vaniloid receptor and subunit of the fol- lowing fates: Incipient or dormant: Microscopic lesions without proliferation sclerosing, regressing, or obsolete: Mature tubular structures in ductal adenocarcinoma composed of malignant cells. Osteomyelitis may affect as many as % of with poi and a giant cell tumor second most common side effects. Ask the pris- oner for a given patient or carer. Cpt- is changed to include older patients may present with an indirect approach by paediatric urologists, ...
Giant cell tumors of the tendon sheath are the second most common tumors in the hand; simple ganglion cysts are the most common. Giant cell tumors of the tendon sheath most commonly occur in patients ... more
Introduction: Giant cell tumor of the tendon sheath (GCTTS) is a benign tumor, originating from proliferation of the synovial cells of a tendon sheath. It is very rare within the pediatric population. Case Report: In this case presentation, we describe two cases of GCTTS in the hand, in a 7-year-old female and a 6-year-old male. Conclusion: GCTTS occurs very uncommonly in children. It is difficult to accurately diagnose on clinical examination and radiological investigation alone, and thorough and complete excision is important to avoid recurrence of the lesion. The two cases presented in this report help further define this condition, in terms of diagnosis and management, in the pediatric population.
(HealthDay)-Turalio (pexidartinib) capsules have been approved to treat adults with symptomatic tenosynovial giant cell tumor (TGCT), the U.S. Food and Drug
Giant-cell carcinoma of the lung (GCCL) is a rare histological form of large-cell lung carcinoma, a subtype of undifferentiated lung cancer, traditionally classified within the non-small-cell lung carcinomas (NSCLC). The characteristic feature of this highly lethal malignancy is the distinctive light microscopic appearance of its extremely large cells, which are bizarre and highly pleomorphic, and which often contain more than one huge, misshapen, pleomorphic nucleus ("syncytia"), which result from cell fusion. Although it is common in the lung cancer literature to refer to histologically mixed tumors containing significant numbers of malignant giant cells as "giant-cell carcinomas", technically a diagnosis of "giant-cell carcinoma" should be limited strictly to neoplasms containing only malignant giant cells (i.e. "pure" giant-cell carcinoma). Aside from the great heterogeneity seen in lung cancers (especially those occurring among tobacco smokers), the considerable variability in diagnostic ...
Kai Wang and Bin Zhu contributed equally to this study and shared the first authorship DOI : 10.5137/1019-5149.JTN.9594-13.1 Three patients with spinal primary diffuse-type tenosynovial giant cell tumor (DTGCT) received surgical treatment in our department between 2002 and 2012. All 3 patients were female and aged 23, 33, and 44 years. The mean time from symptom onset to diagnosis was 17 months (range, 5-24 months). One case involved the C1 right lateral mass and C2 vertebral body, the second involved the C1-2 left lateral masses and C2 vertebral body, and the third involved the C5-7 left lateral mass and C6 vertebral body. All patients underwent computed tomographyguided biopsy to confirm the diagnosis of tenosynovial giant cell tumor. Gross total resection was achieved in all patients, including 2 piecemeal resections and 1 en-bloc resection. The mean follow-up time was 6 years (range, 1-11 years), and there was no sign of recurrence in the patients. Seventy cases have been identified so far ...
Sarcoma is a peer-reviewed, Open Access journal dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposis sarcoma, are published as well as preclinical and animal studies.
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
hey guys, im new to the community. i am in real need of help. my mom has had visible hard lump growing on her pinky finger the past month. it is about 1cm long and protrudes from the inner portion ...
Giant cell tumor (GCT) is a benign, locally aggressive tumor that rarely occurs in the spine. They usually occur in patients between 20 and 40 years of age; some patients with GCT present in hospital with pregnancy. The management of these patients can be challenging. The current study reports a case of GCT located in the sixth thoracic vertebra of a 31-year-old female at 34 weeks of gestation. An osteolytic lesion, 3.5 cm × 3.5 cm in diameter, was identified on CT. An MRI test of the lesion revealed a soft tissue mass involving the T 6-7 vertebrae, extending to the right pedicle of the T 6 vertebra and causing significant spinal cord compression ...
Behjati Sam, , Tarpey Patrick Campbell Peter, J., Presneau, Nadège, Pillay Nischalan, , Van Loo Peter Hassan A Bassim, , Wedge David C., , Cooke, S.L., Gundem, G., Davies, H., Nik-Zainal, S., Martin, S., McLaren, S., Goody, V., Robinson, B., Butler, A., Teague, J.W., Halai, D., Khatri, B., Myklebost, O., Baumhoer Daniel, , Jundt Gernot, , Hamoudi Rifat Wedge David, C., Tirabosco, R., Amary, M.F., Futreal, P.A., Stratton, M.R., Campbell Peter J., , Flanagan, A.M., Scheipl Susanne, and Goodie Victoria, (2013) Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genetics, 45 (12). pp. 1479-1482 ...
Article Recent advancements in numerical modelling of flow and dispersion in urban areas: a short review. This paper reviews recent findings in the field of flow and pollutant dispersion modelling around buildings and within complex urban geometries....
Nowadays, biologists can explore the cell at the nanometre level. They discover an unsuspected world, amazingly overcrowded, complex and heterogeneous, in which water, also, is complex and heterogeneo
Heres a good short review on a subject that doesnt come up too often in drug discovery, but can be a major headache when it does: atropisomerism. There are
Heres a good short review on a subject that doesnt come up too often in drug discovery, but can be a major headache when it does: atropisomerism. There are
100 Years Ago: September 1917 This is my thirty-third installment in a series of short reviews of National Geographic Magazines from a century ago. As y…
In this section, your ideas for IYC2011 can start to become reality. Here, you can submit activities for consideration and, after a short review, they will be listed below and any related events will populate the IYC calendar. Activities listed here have a clearly defined theme and describe how, when, and where they will take place ...
In this section, your ideas for IYC2011 can start to become reality. Here, you can submit activities for consideration and, after a short review, they will be listed below and any related events will populate the IYC calendar. Activities listed here have a clearly defined theme and describe how, when, and where they will take place ...
We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time.Find out more ...
In this review, we highlight the complexities of the natural history, biology, and clinical management of three intermediate connective tissue tumors: desmoid tumor (DT) or aggressive fibromatosis, tenosynovial giant cell tumor (TGCT) or diffuse-type pigmented villonodular synovitis (dtPVNS), and giant cell tumor of bone (GCTB). Intermediate histologies include tumors of both soft tissue and bone origin and are locally aggressive and rarely metastatic. Some common aspects to these tumors are that they can be locally infiltrative and/or impinge on critical organs, which leads to disfigurement, pain, loss of function and mobility, neurovascular compromise, and occasionally life-threatening consequences, such as mesenteric, bowel, ureteral, and/or bladder obstruction ...
Giant cell tumor of the tendon sheath (GCTTS) occurs most often in the hand and rarely in the feet, and as an extremely uncommon presentation in the knee joint. Case reports involving GCTTS in the knee joint generally describe it originating from the nearby anterior cruciate ligament, posterior cruciate ligament, patellar tendon, and medial plica. To the best of our knowledge, there are no previously reported case reports involving GCTTS originating in the ligamentum mucosum. In this article, we describe a 27-year-old male patient who was admitted to the orthopedic emergency room with a painful locked knee. He had severe pain that was worse with activity and a decreased range of motion. Magnetic resonance imaging (MRI) indicated massive swelling and a well- circumscribed lobulated intraarticular mass at the distal one third of the ligamentum mucosum. The mass was removed successfully with arthroscopic-assisted mini-open excision, and histological analysis subsequently diagnosed it as a localized ...
Giant cell tumour (GCT) or osteoclastoma is a very rare locally invasive bone tumour that occurs close to the joint. The ulnar metaphysis is an unusual site for an Osteoclastoma with occurrence rate of 0.45% to 3.2% as reported in literature [1]. Most of the patients seek traditional methods of treatment before orthopaedic consultation and present lately with extensive involvement of the tumour into soft tissues and articular surface, making the joint preservation difficult or impossible. For reconstruction, several options have been described, which include fibular autografts, allografts and cement augmentation. Inherent to all these procedures is the risk of delayed union of the graft and preserving functional mobility of the joint. We report a rare case of a proximal ulna GCT diagnosed in a 13-year-old girl. It was treated with intralesional curettage, and autologous maternal iliac crest bone grafting augmented with bone cement reconstruction.
Nicole Del pine r alise de nombreuses publications au niveau national et international : European Federation of National Associations of Orthopaedics and Traumatology, Bone cementation of giant-cell tumor. About 37 cases with long term follow up.
We report a craniofacial approach for resection of a giant-cell tumor of the sphenoid bone. Complementary radiotherapy was performed because of the incomplete tumor remotion. Four-year follow-up is presented.
Case Reports in Surgery is a peer-reviewed, Open Access journal that publishes case reports related to all aspects of surgery. Topics include but are not limited to oncology, trauma, gastrointestinal, vascular, and transplantation surgery.
In the single dose Part A of the study, patients receive 1 dose of of 10 mg/kg MCS110 administered i.v. on Day 1.. In the multiple dose Part B patients receive up to 6 doses of 10 mg/kg MCS110 administered i.v. once every 4 weeks starting at Day 1, or at Day 29 if the first dose received was placebo.. In the multiple dose Part C patients receive up to 6 doses of 3 mg/kg or 5 mg/kg or 10 mg/kg MCS110 administered i.v. once every 4 weeks starting at Day 1. ...